CSL Ltd Annual Report 2019

17 During 2018/19, neither CSL Behring Australia nor Seqirus Australia were found to be in breach of the MA Code. For international operations, CSL (including CSL Behring and Seqirus) was not found to be in breach of any regulation of the US FDA or the European Medicines Agency (EMA) with respect to the promotion or marketing of medicines, vaccines and therapies. Our expanding footprint CSL reaches patients in more than 70 countries and we continue to deliver on our promise to make our novel therapies available to patients around the world. The Commercial Operations Senior Leadership Team oversees the delivery of our marketplace strategy and the CSL Board has strategic oversight and monitors performance through key subcommittees. The decision to enter newmarkets is a long-term commitment driven by a desire to understand and respond to patients’ needs. We continue to see the benefits of our expanding footprint, including double-digit growth from our local investments in the developing countries of Russia, Turkey and within Latin America. While we invest locally to improve disease awareness and access to medicines, we also bring global benefits to the markets we serve. Our people are passionate about connecting local healthcare providers and other stakeholders to the global rare disease community, which in turn accelerates their ability to learn and exchange best practice. * Indicator externally assured by Ernst & Young. 0 breaches of product marketing and promotional activities by the US FDA, EMA or Medicines Australia.* CSL Limited Annual Report 2019 30 A Trusted Health Partner Highlights for the reporting period include the following: Argentina In April, Seqirus formally launched its operations in Argentina, working with local partners to supply influenza vaccines to the national Ministry of Health. The vaccines are then provided to the public to help prevent seasonal influenza. Argentina will act as a hub for further expansion across Latin America. China CSL Behring completed its acquisition of plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. fromHumanwell Healthcare Group Co. Ltd in August 2017 and acquired the remaining 20% equity in 2018. The acquisition provides CSL with a strategic presence in the Chinese domestic plasma fractionation market and complements the leadership position that CSL Behring has built over the past 20 years as a provider of imported albumin in China. It also enables CSL to continue expanding our commercial footprint and contributing our global expertise for the benefit of patients with rare and serious diseases in China. Dubai CSL Behring established new regional headquarters at Dubai Science Park, strengthening the company’s presence in the Middle East and Africa region, where we have seen increasing demand for our medicines. Emerging Europe In August, CSL Behring transformed its presence in Poland, Hungary, and the Czech Republic into fully fledged, independent affiliates. This resulted in each affiliate obtaining full legal entity status, together with a licence for wholesale activities. Korea CSL Behring established a new office in South Korea. This is the first step to strengthening our market presence and delivering CSL Behring’s promise to care for patients and strengthen the public health. France In June, Seqirus signed a distribution agreement with French pharmaceutical marketer Laboratoire Arrow to enter the French market. Whilst a date has not yet been set for the formal launch of FLUCELVAX ® TETRA, this agreement is a great milestone in our journey to provide influenza protection to the people of France.